History of escozine for pets
This presentation is the property of its rightful owner.
Sponsored Links
1 / 8

HISTORY OF ESCOZINE FOR PETS™ PowerPoint PPT Presentation


  • 32 Views
  • Uploaded on
  • Presentation posted in: Pets / Animals

The information contained in this document is subject to national and International Copyright© laws and is the proprietary and exclusive property of PetLife Pharmaceuticals, except as otherwise indicated. No part of this document, in whole or in part, may be reproduced, stored, transmitted, or used for design purposes without the prior written permission of PetLife Pharmaceuticals. The information contained in this document is subject to change without notice. The information in this document is provided for informational purposes only. Privacy Information: This document may contain information of a sensitive nature. This information should not be given to persons other than those who are involved with PetLife Pharmaceuticals, or who will become involved during the lifecycle.

Download Presentation

HISTORY OF ESCOZINE FOR PETS™

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


History of escozine for pets

PETLIFE™ - White Paper

HISTORY OF ESCOZINE FOR PETS™

Table of Contents

I.

Escozine For Pets™ verses Escozul / Vidatox ....................................................................... 2

II.

Patent ................................................................................................................................................ 2

III.

Labiofam ........................................................................................................................................... 2

IV.

Location / Natural Habitat of the Caribbean Blue Scorpion ................................................ 3

V.

Confirmation from Atheris Laboratory, Switzerland ............................................................. 4

VI.

Summary .......................................................................................................................................... 5

(310) 279-5154

[email protected]

www.petlifepharma.com

The information contained in this document is subject to national and International Copyright© laws and is

the proprietary and exclusive property of PetLife Pharmaceuticals, except as otherwise indicated. No part

of this document, in whole or in part, may be reproduced, stored, transmitted, or used for design purposes

without the prior written permission of PetLife Pharmaceuticals. The information contained in this document

is subject to change without notice. The information in this document is provided for informational purposes

only. Privacy Information: This document may contain information of a sensitive nature. This information

should not be given to persons other than those who are involved with PetLife Pharmaceuticals, or who will

become involved during the lifecycle.

History of Escozine For Pets™

2014

1


History of escozine for pets

PETLIFE™ - White Paper

A NEW CANCER FORMULATION DERIVED FROM BLUE SCORPION VENOM.

I.

Escozine For Pets™ verses Escozul / Vidatox

PetLife Pharmaceuticals and its sister company, Medolife, are the only companies in the

world which have the patented formulation based upon blue scorpion venom. Medolife’s

Escozine is the first alternative natural medication recognized for oncological treatments

by the Ministry of Health, Food and Drug Administration, of the Dominican Republic.

PetLife owns the exclusive rights to all veterinary uses of the patented formulation and

technology. Although based on the same Blue Scorpion venom compound, Escozine™

and Escozine for Pets™ have many advantages over Escozul and Vidatox which are

illustrated below in the history and comparison of the products.

Patent

II.

PetLife owns exclusive veterinary rights to Arthur Mikaelian’s patent which achieved a full

patent in 2012 for the bioactive peptide (Blue Scorpion Venom) and polarization

technology (Patent # US 8,097,284 B2). This unique patented polarization technique

escalates the highly positive charges in the extracellular membrane of main compounds

in Escozine For Pets™. This gives them the ability to function as a transportation

mechanism; it also intensifies the binding preferences with malignant cells.

The Patented Mikaelian Polarization technology plays an essential role in potentiating the

Blue Scorpion Venom and delivering more active ingredients directly into cancerous cells

in comparison to non-polarized ingredients. This technology allows fewer compounds to

be used and allows large scale commercialization of the natural version.

PetLife’s exclusively owned bioactive peptide (Blue Scorpion Venom) and polarization

technology for veterinary use is the base for a novel pharmacologically active compound

which is critical in numerous new generation essential drugs and Nutraceuticals for

veterinary use.

III.

Labiofam

The Cuban laboratory, Labiofam, has no registration, patent or completed scientific

research regarding Escozul to make an adequately supported presentation of this product

to a regulatory agency or, for that matter, to the public. Further, actual production quality

control for medication of ESCOZUL does not exist at this time. Labiofam has completely

stopped the production of Escozul and it has been replaced by Vidatox, which is a

homeopathic version which has been diluted 1:1,000. We have a spectrophotometer

analysis of Vidatox which shows no evidence of venom.

The website, www.escozul-cancer.com, contains useful technical and scientific

information regarding Escozul. However, it also simultaneously posts misleading

History of Escozine For Pets™

2014

2


History of escozine for pets

PETLIFE™ - White Paper

information alleging (with noticeable exaggeration) that Labiofam is the “only” company

who is entitled to engage in the research and production of Escozul. In fact, the

Guantanamo group as specifically mentioned in this website is the original group who

initiated the blue scorpion medication project. The former leader was Michel Bordier, the

scientist who discovered the effect of blue scorpion venom. The Guantanamo group has

more case studies and experience with blue scorpion venom than Labiofam. However,

the Guantanamo group is presented on the website as a company who does not possess

the right or knowledge to conduct research and development of Escozul. Dr. Mikaelian

was present and indeed witnessed Labiofam doctors employing statistical analyses and

protocols created by the Guantanamo group. After the death of Michel Bordier, the

Guantanamo group stopped being active and they lost their position as a leading research

group. Michel Bordier did not apply for any patent or any legal registration or claims.

This is only one of many distortions of the real facts regarding the origin, development

and sale of Escozul. Collectively these distortions appear to be an actively orchestrated

propaganda campaign to promote Labiofam as the only legitimate provider of Escozul.

Beyond the obvious, it would appear these misrepresentations benefit the tourist

economy of Cuba. Since Labiofam was not free to market its product internationally and

was not prepared to meet the demands of ongoing production and distribution, significant

numbers of tourists used to travel to Cuba to receive the medication, under the false belief

that it is free. The actual cost of Escozul under these circumstances was prohibitive for

most of the general public, who have need of it.

IV.

Location / Natural Habitat of the Caribbean Blue Scorpion

Another significant misstatement made on the website is that the blue scorpions only

inhabit the island of Cuba. Medolife has scientific proof that proves that this is false. A

scorpion which is identical to the Cuban blue scorpion has been confirmed to inhabit the

Dominican Republic. The technical name of the Cuban blue scorpion is Rhopalurus

junceus (Buthidae family); and the technical name of the Dominican blue scorpion is

Rhopalurus princeps (also Buthidae family). Cuban biologists Armas and Prendini have

confirmed that these scorpions are of the same species. Additionally, this has been

confirmed by Atheris Laboratory in Switzerland.

Rhopalurus princeps, (Karsch, 1879)

By: Michiel Cozijn

“Morphological Information Rhopalurus princeps seems more closely

related to the Cuban

Rhopalurus species (Prendini et al, 2009).”

See http://www.ntnu.no/ub/scorpion-files/r_princeps_biography.pdf.

History of Escozine For Pets™

2014

3


History of escozine for pets

PETLIFE™ - White Paper

In 2007 Medolife signed a contract with the Ministry of Environment of Dominican

Republic and started expeditions and located Rhopalurus princeps with local scientist and

biologist Kelvin A. Guerrero.

See Kelvin A. Guerrero’s. website: 2007-2011: Consultant Entomologist and Research

Advisor for Medolife Corporation for the research: Investigation on the Biochemistry and

Ecology of the Species of Scorpion of the Family Buthidae in the Dominican Republic in

order to identify potential organic of the scorpion venom compound that can be beneficial

to cure cancer disease on human.

The source: http://kguerrero.net/consulting.html

V.

Confirmation from Atheris Laboratory, Switzerland

In 2009, the venom of Rhopalurus junceus (Cuban blue scorpion) and the venom of

Rhopalurus princeps (Dominican Republic blue scorpion) were sent by Medolife to

Switzerland's world famous Atheris laboratory (http://atheris.com) for identification of

these two venoms. (As background, Atheris laboratory helped Trans-molecular Inc. to

identify Chlorotoxin, one of the main components in Buthidae family scorpion venom. See

the following links to obtain more details and information regarding this study.

http://en.wikipedia.org/wiki/Chlorotoxin and http://www.transmolecular.com)

Atheris Laboratory has provided scientific confirmation to Medolife that both scorpion

venoms block sodium and potassium volt gate channels. (Please read letter reprinted

below from Atheris.) This action causes actual shrinkage of tumors and inhibits cancer

cell proliferation. Interestingly, the report (MALDI-TOF-MS) analyses from Atheris

laboratory indicates that Dominican blue scorpion venom has a three times higher

concentration of Chlorotoxin, which is one of the main components with anti tumoral

properties and also has smaller molecular weight than the Cuban blue scorpion venom,

which makes Escozine For Pets™ more effective in the penetration of cancer cell

membranes and more therapeutic compound passes through the blood–brain barrier

(BBB).

History of Escozine For Pets™

2014

4


History of escozine for pets

PETLIFE™ - White Paper

The following is a copy of the letter from Atheris Laboratory: <See the original letter

attached>

Dear Arthur Grant Mikaelian PhD,

Please find attached both certificates of analysis concerning Rhopalurus

princeps and R. junceus.

These analyses allowed the detection of numerous components in both

venoms. Spectra clearly display signals that are consistent with scorpion

venoms with two major sets of masses, the first one located around 3-4 kDa

(mainly potassium channel inhibitors) and the second one at 6-8 kDa

(mostly sodium channel inhibitors).

We hope these analyses correspond to your expectations.

Best regards,

Philippe Favreau

03/30/2010

Philippe Favreau

Atheris Laboratories

CP 314

1233 Bernex - Geneva

Tel: 0041 22 850 05 85

Fax: 0041 22 850 05 86

PetLife note: The “two certificates’ referenced directly contain information deemed

proprietary and are not included in this White Paper. Select prospective partners or investors

may be granted access to the certificates, for due diligence purposes, under NDA.

VI.

Summary

Dr. Mikaelian is currently the only scientist who has completed all research and the

development process and has attained the legal registration to commercialize the Blue

Scorpion venom based product. This patent and technology has been licensed to PetLife

Pharmaceuticals for commercialization.

Escozine For Pets™ is solely owned and commercialized by PetLife Pharmaceuticals.

PetLife’s sister company, Medolife, owns and markets the human product, Escozine. The

product, Escozul, is not produced or sold by Medolife and neither Medolife nor PetLife

rely on this product in any way.

History of Escozine For Pets™

2014

5


History of escozine for pets

PETLIFE™ - White Paper

PetLife in association with Medolife has its own independent source of Blue Scorpion

venom in the Dominican Republic and has established the world’s first Scorpion

reservation which is 50,000 square meters and can produce millions of doses to meet

global demand.

History of Escozine For Pets™

2014

6


History of escozine for pets

PETLIFE™ - White Paper

History of Escozine For Pets™

2014

7


  • Login